MedTrace Logo

Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer

NCT04311762 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-10-31

No results posted yet for this study

Summary

The goal of the study is to identify the maximum tolerated dose of endobronchial ultrasound-guided transbronchial injection (EBUS-TBNI) of cisplatin for Stage IV lung cancer.

Conditions

  • Lung Cancer Metastatic

Interventions

DRUG

cisplatin

Intratumoral delivery of cisplatin via bronchoscopy (endobronchial ultrasound)

Sponsors & Collaborators

  • University of Vermont Medical Center

    collaborator OTHER

  • University of Vermont

    lead OTHER

Principal Investigators

  • C. Matthew Kinsey, MD, MPH · University of Vermont

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2029-03-01
Completion
2029-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04311762 on ClinicalTrials.gov